Frontotemporal Lobar Degeneration Clinical Trial
Official title:
Treatment Study for Frontotemporal Dementia
Verified date | June 1, 2009 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Objectives. The proposed clinical study has two goals: First, to assess the efficacy of a
central nervous system stimulant and an atypical antipsychotic in treating the behavioral
symptoms of FTD and second, to further characterize the biological markers, including
genetic, imaging, and CSF proteins, of FTD in relation to our existing group of Alzheimer's
patients.
Rationale. Frontotemporal dementia (FTD) is increasingly recognized as an important
neuropsychiatric disorder. Symptoms of FTD include disinhibition, impulsivity, apathy,
affective lability, and language dysfunction. The clinical syndrome is associated with
frontal and/or anterior temporal atrophy on imaging and autopsy. Levels of the CSF proteins
tau and (Beta)-amyloid 1-42, shown to have diagnostic utility in patients with Alzheimer's
Disease (AD), have also been found to be abnormal in FTD. FTD is less associated with APOE
genotype than AD, however some familial cases of FTD are associated with specific mutations
in the gene encoding the tau protein. Currently, no treatments have been proven to be
effective for altering the course or clinical symptoms of FTD.
Design. Study subjects will include 50 male and female patients with mild-moderate
frontotemporal dementia recruited from participants in NINDS protocol 02-N-0001. In a
double-blinded crossover 11-week study without a placebo control, patients will be treated
with a stimulant (dextroamphetamine) and an atypical antipsychotic (quetiapine). The primary
outcome measures will be the Neuropsychiatric Inventory and the Clinical Global Impression of
Change. Cerebrospinal fluid, cognitive and genetic measures, brain MRIs, and side effects
scales will also be collected.
Status | Completed |
Enrollment | 20 |
Est. completion date | June 1, 2009 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 95 Years |
Eligibility |
- INCLUSION CRITERIA: 1. FTD as diagnosed by the Lund-Manchester criteria including patients with diagnoses of Semantic Dementia or Primary Progressive Aphasia. 2. Ages 45 to 95 years old. 3. Mild-to-moderate (CDR 1 to 2) FTD with an assigned durable power of attorney. EXCLUSION CRITERIA: 1. Diagnosis of any form of dementia besides FTD, including AD, Lewy body dementia, vascular dementia, dementia associated with Parkinson's disease, Corticobasal Degeneration and Progressive Supranuclear Palsy. 2. Severe dementia (CDR 3). 3. Known allergy or serious adverse reaction to quetiapine or dextroamphetamine. 4. Patient is already receiving a stimulant (methylphenidate, dextroamphetamine, pemoline, or modafinil), or an antipsychotic medication, typical or atypical, including prochlorperazine and metoclopromide. 5. Patients taking any of the following medications because of their potential interaction with dextroamphetamine: MAO use currently or within 14 days prior to start of study, Furazolidone, Guanethidine, norepinephrine, sibutramine, tricyclic antidepressants, carbonic anhydrase inhibitors. 6. Patients taking the following medications because of their potential interaction with quetiapine: Carbamazepine, clozapine, lithium, thioridazine. 7. History of CVA, or at significantly increased risk for CVA (e.g., atrial fibrillation, recent TIA etc.). 8. Symptomatic cardiovascular disease (i.e., angina, claudication, TIAs, syncope), uncontrolled hyper or hypotension, or a tic disorder. 9. Any medical contraindication to performing the procedures involved in the study including blood draws or lumbar puncture. 10. We will require a woman of child-bearing age to have a pregnancy test prior to starting the study medications and to use contraception during the course of the study. 11. Patients with a previous negative trial of a stimulant. 12. Patients with a history of severe psychosis. 13. Patients with a history of recent substance abuse. 14. Patients with QTc prolongation on a baseline EKG. 15. A score of 2 or less on the Communication Functional Ratings - Swallowing Domain. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Galynker I, Ieronimo C, Miner C, Rosenblum J, Vilkas N, Rosenthal R. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci. 1997 Spring;9(2):231-9. Review. — View Citation
Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry. 1989 Jul;50(7):241-9. Review. — View Citation
Woods SW, Tesar GE, Murray GB, Cassem NH. Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry. 1986 Jan;47(1):12-5. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Active, not recruiting |
NCT04516499 -
Neurofilament Surveillance Project (NSP)
|
||
Recruiting |
NCT05456503 -
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620
|
Phase 3 | |
Recruiting |
NCT03030586 -
ADDIA Proof-of-Performance Clinical Study
|
||
Completed |
NCT02590276 -
Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)
|
N/A | |
Completed |
NCT00677885 -
P-glycoprotein Function in Brain Diseases
|
||
Completed |
NCT02333942 -
Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia
|
||
Completed |
NCT00187525 -
A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
|
Phase 4 | |
Recruiting |
NCT05741853 -
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
|
N/A | |
Completed |
NCT02213458 -
Care Ecosystem: Navigating Patients and Families Through Stages of Care
|
N/A | |
Completed |
NCT04287738 -
Care Ecosystem: Navigating Patients and Families Through Stages of Care, Extension Trial
|
N/A | |
Active, not recruiting |
NCT04937452 -
Dopaminergic Therapy for Frontotemporal Dementia Patients
|
Phase 2 | |
Completed |
NCT03606798 -
Multidisciplinary and Personalized Care of Behavioral Disorders in Frontotemporal Lobar Degeneration.
|
N/A | |
Recruiting |
NCT01962064 -
Social Cognition in Ageing and in Frontotemporal Lobar Degeneration
|
N/A | |
Recruiting |
NCT05956834 -
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
|
||
Enrolling by invitation |
NCT04635540 -
Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease
|
N/A | |
Completed |
NCT00604591 -
Effects of Tolcapone on Frontotemporal Dementia
|
Phase 2 | |
Completed |
NCT03508024 -
Patients With Alzheimer's Disease or Related Youth Disease
|
||
Completed |
NCT00613119 -
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
|
||
Recruiting |
NCT02964611 -
Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration
|